Sugi Predict

Sugi Predict / Compounds / SCHEMBL3553532

SCHEMBL3553532

SCHEMBL3553532

Cc1c(C(=O)c2ccc(Cl)cc2Cl)oc2cc(-c3cccc(NS(C)(=O)=O)c3)ccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 1/20 0.43
▸ HSD17B3 P37058 1/20 0.43
▸ HSD17B1 P14061 2/20 0.39
▸ HSD17B2 P37059 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KIF11 P52732 1/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ RAF1 P04049 1/20 0.38
▸ MAP2K1 Q02750 1/20 0.38
▸ GPR27 Q9NS67 1/20 0.38
▸ P2RX7 Q99572 1/20 0.38
▸ AAK1 Q2M2I8 1/20 0.38
▸ BRD4 O60885 2/20 0.38
▸ FLT1 P17948 1/20 0.37
▸ FLT4 P35916 1/20 0.37
▸ KDR P35968 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5012034 0.90 HSD17B3 (0.42) HSD17B3HSD17B1HSD17B2CYP1A2CYP3A4
SCHEMBL13335808 0.89 HSD17B3 (0.42) HSD17B3HSD17B1HSD17B2CYP1A2CYP3A4
SCHEMBL3105545 0.88 HSD17B3 (0.41) HSD17B3HSD17B1HSD17B2CYP1A2CYP3A4
SCHEMBL3558074 0.88 HSD17B3 (0.41) HSD17B3HSD17B1HSD17B2CYP1A2CYP3A4
SCHEMBL3557513 0.87 MCL1 (0.48) MCL1MAPTTHRB
SCHEMBL3088879 0.87 KIF11 (0.45) HSD17B3HSD17B1HSD17B2CYP1A2CYP3A4
SCHEMBL3560389 0.86 MCL1 (0.52) MCL1CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL3105125 0.86 NPC1 (0.41) HSD17B3HSD17B1HSD17B2CYP1A2CYP3A4
SCHEMBL5010939 0.85 MCL1 (0.43) MCL1MAPTTHRB
SCHEMBL3559001 0.84 MCL1 (0.41) MCL1AAK1BRD4FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7659412-B2 Benzofuran derivatives useful for treating hyper-proliferative disorders BAYER HEALTHCARE LLC (US) 2010-02-09 — — US disclosed
US-20090023783-A1 BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS ZHANG CHENGZHI 2009-01-22 — — US disclosed
US-7420066-B2 Benzofuran derivatives useful for treating hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION (US) 2008-09-02 — — US disclosed
US-20060194816-A1 Benzofuran derivatives useful for treating hyper-proliferative disorders BAER PHAMACEUTICALS CORPORATION (US) 2006-08-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194816-A1 Benzofuran derivatives useful for treating hyper-proliferative disorders MKI67, PCNA, CCNI MCL1 55/4885HSD17B3 572/4885HSD17B1 271/4885
US-20090023783-A1 BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS PCNA, MKI67, CDK4 MCL1 57/4885HSD17B3 1071/4885HSD17B1 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.